|
Association of CD44+/CD24- phenotype with clinical characteristics |
||||
| Characteristic |
All tumors (n = 240) |
Negative (0%) (n = 165) |
Positive (> 0%) (n = 75) |
P valuea |
|
|
||||
| Median age (years) |
64.1 |
64.3 |
63.5 |
1.0 |
| Menopausal status |
0.098 |
|||
| Premenopausal |
42 (18) |
24 (15) |
18 (24) |
|
| Postmenopausal |
198 (83) |
141 (85) |
57 (76) |
|
| Tumor size |
0.58 |
|||
| > 20 mm |
183 (76) |
143 (75) |
40 (80) |
|
| ≤ 20 mm |
57 (24) |
47 (25) |
10 (20) |
|
| Lymph node status |
0.19 |
|||
| Positive (n > 0) |
159 (66) |
114 (69) |
45 (60) |
|
| Negative (n = 0) |
81 (34) |
51 (31) |
30 (40) |
|
| S-phase fraction |
1.0 |
|||
| High (> 12%) |
37 (26) |
29 (26) |
8 (27) |
|
| Low (< 12%) |
106 (74) |
84 (74) |
22 (73) |
|
| Missing |
97 |
|||
| Histologic type |
< 0.001 |
|||
| Ductal |
176 (77) |
119 (77) |
57 (78) |
|
| Lobular |
28 (12) |
23 (15) |
5 (7) |
|
| Lobular + ductal |
13 (6) |
11 (7) |
2 (3) |
|
| Medullary |
8 (4) |
0 (0) |
8 (11) |
|
| Other |
3 (1) |
2 (1) |
1 (1) |
|
| Missing |
12 |
|||
| Estrogen receptor |
0.45 |
|||
| Positive (> 25 fmol/mg) |
159 (68) |
112 (70) |
47 (64) |
|
| Negative |
74 (32) |
48 (30) |
26 (36) |
|
| Missing |
7 |
|||
| Progesterone receptor |
0.89 |
|||
| Positive (> 25 fmol/mg) |
114 (49) |
79 (49) |
35 (48) |
|
| Negative |
119 (51) |
81 (51) |
38 (52) |
|
| Missing |
7 |
|||
| HER2 |
0.002 |
|||
| Strong (score = 3) |
38 (16) |
34 (21) |
4 (5) |
|
| Weak/negative |
202 (84) |
131 (79) |
71 (95) |
|
| Cytokeratin 5/14b |
0.012 |
|||
| Strong |
28 (13) |
17 (10) |
11 (25) |
|
| Weak/negative |
188 (87) |
155 (90) |
33 (75) |
|
| Missing |
24 |
|||
| Epidermal growth factor receptorc |
||||
| Strong |
27 (11) |
12 (7) |
15 (20) |
|
| Weak/negative |
210 (89) |
150 (93) |
60 (80) |
|
| Missing |
3 |
|||
| Distant metastasis |
1.0 |
|||
| Positive |
73 (30) |
50 (30) |
23 (31) |
|
| Negative |
167 (70) |
115 (70) |
52 (69) |
|
|
Data presented as n (%). aP values were calculated using Fisher's exact test, except for age where the Mann-Whitney U test was used. The missing categories were always excluded. bScoring as previously described [12]. cScoring as previously described [20]. | ||||
Honeth et al. Breast Cancer Research 2008 10:R53 doi:10.1186/bcr2108 |
||||